Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma

Abstract Development of anti-drug antibodies (ADAs) can interfere with therapeutic monoclonal antibodies and may lead to drug neutralisation and clinical disease progression. Measurement of circulating drug levels and development of ADAs in the setting of anti-programmed cell death-1 agent pembroliz...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: S. C. Sasson, L. E. Wilkins, R. A. Watson, C. Jolly, O. Brain, P. Klenerman, A. Olsson-Brown, B. P. Fairfax
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/bb9be8f3099e4082999b755983e9f62a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!